Eli Lilly was successful in a crucial legal battle on Monday when a U.S. District Judge in Indianapolis upheld the validity of its U.S. patent for the drugmaker' s blockbuster lung-cancer drug, Alimta.
Eli Lilly was successful in a crucial legal battle on Monday when a U.S. District Judge in Indianapolis upheld the validity of its U.S. for the drugmaker' s blockbuster lung-cancer drug, Alimta.
s,
Teva Pharmaceutical Industries
he '209
a
The court said the defendantLtd, APP Pharmaceutical, now known as Fresenius Kabi USA LLC, Barr Laboratories Inc and Pliva Hrvatska D.O.O., failed to show by clear evidence that the asserted claims of tre invalid.
However, the decision that would preserve the $2.6 billion-a-year drug from generic competition until 2022, could change if generic drug companies appeal the ruling.
Read the complete report here:
Source: Reuters
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen